INTRODUCTION

There is little literature reporting on the efficacy of bone marrow aspirate concentrate (BMAC) in conjunction with hip arthroscopy.

PURPOSE

We sought to systematically review the literature on BMAC use following hip arthroscopy, in particular, whether its use results in improved patient-reported outcome measures (PROMs).

METHODS

The Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines were followed when querying PubMed, Cochrane Central Register of Controlled Trials, and Scopus in January 2023. Articles were included if they reported on pre- and postoperative outcomes for patients undergoing hip arthroscopy with concomitant BMAC and were written in English.

RESULTS

Five articles were included in the review. A total of 252 hips undergoing BMAC and hip arthroscopy performed between 2010 and 2020 were evaluated. The average age of patients in the studies ranged between 32.8 and 48.5 years. All studies reported improved postoperative PROM scores compared to preoperative outcome scores after BMAC and hip arthroscopy. Two studies reported survivorship of 100% and 85.7%. All 5 studies conducted a subanalysis between BMAC and hip arthroscopy and a control group. Three studies reported superior outcomes in the BMAC and hip arthroscopy group, while another study reported findings that trended toward favoring the BMAC and hip arthroscopy group but that did not reach statistical significance.

CONCLUSION

BMAC may improve outcomes in patients undergoing hip arthroscopy. However, due to the small sample size and lack of standardized control groups, the results of this systematic review are inconclusive.